Alzheimer's
The latest sourced reporting on Alzheimer's from Dementias Today: dated, and plain about what the evidence does and does not show.
A University of Michigan pilot of the Roadmap app found dementia caregivers logged a positive activity on 87 percent of days, and reported less stress on the days they did. It was a feasibility study, with no control group, and the authors say the real trial has not happened yet.
In a single-arm pilot of 48 Chinese American dementia caregivers, positive views of caregiving rose 96 percent after a seven-week Chinese-language program delivered entirely through WeChat. Burden and depression stayed where they were, and there was no comparison group.
COSMOS tested a daily multivitamin against placebo in more than 21,000 American seniors and found a small, repeatable slowing of cognitive aging. It is one of the only supplement results in dementia prevention that has held up, and it is smaller than the headlines suggest.
A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.
A new review proposes that expecting to think clearly, or expecting to fail, draws on the same limited pool of mental control the task itself needs. The evidence is thin in exactly the places families care about most, and the authors say so.
A new review gathers the scattered research on placebo and nocebo effects in memory into one account. In a separate online trial, healthy adults aged 65 to 80 who were told an inert sound would blunt their attention stopped improving at a task everyone else improved at.
A triple-blind trial at UZ Leuven randomises colon-release short-chain fatty acid capsules against placebo, then injects every volunteer with bacterial endotoxin and measures what happens to working memory, inhibition and task switching. It is a cause test in a field built mostly on correlations.
An MIT team knocked out every protein-coding gene, one at a time, in human oligodendrocytes carrying APOE4. The trail led to Wnt signaling, an enzyme called GSK3B, and fat droplets where insulation should be. It led there in dishes, organoids and mice, and in no patient yet.
A six-month randomized trial in Istanbul put 60 people with early to mid stage Alzheimer's on a plant-rich ketogenic diet with intermittent fasting. The cognitive gain sat with the 19 participants whose glucose handling was intact, and much less with the 11 whose metabolism was already struggling. The subgroup is tiny. The question it raises is not.
A mathematician at Mississippi State has published a model of how metal ions drive amyloid-beta aggregation, and of what chelators and inhibitors do to that process in simulation. The paper's own claim is modest: a tool for designing experiments. The trials that tried stripping metal out of real brains are the reason that modesty matters.
A narrative review published in Nutrients on 29 July 2026 gathers the evidence that short-chain-fatty-acid-producing bacteria thin out during the silent, amyloid-positive stage of Alzheimer's. It also says, plainly, that nobody yet knows which end of the story came first.
A new scoping review pulls 108 studies on gardens, green space and outdoor programs into one picture. What it shows is real. What it leaves blank matters just as much.
Nine Italian memory clinics signed up to test whether a structured daily diary of behaviour beats standard care at lightening the load on families. Three years after the trial was registered, the results have not appeared.
A review accepted on 1 September 2026 in Frontiers in Molecular Neuroscience argues that mitohormesis, the idea that mild mitochondrial stress makes cells more resilient while relentless stress wrecks them, is a useful framework for linking metabolic disease to dementia risk. It is a framework, the authors stress, not a proven mechanism.
A peer reviewed protocol lays out a 160 person randomized trial testing whether a mobile app, Brain CareNotes, that structures what family care partners report about behavioral symptoms of Alzheimer's and related dementias eases caregiver burden and those symptoms. The trial is still enrolling; no effectiveness results exist yet.
A small randomized trial of 36 caregiver-dyads in South Korea found that a mobile app translating caregiver-logged behavior into individualized, nonpharmacological activity suggestions was associated with lower overall behavioral and psychological symptoms, less agitation and depression, better nighttime sleep efficiency, and higher caregiver confidence, researchers reported.
A PNAS study grew skin cells from cognitively impaired seniors in the lab and timed their internal clocks. Cells with a longer natural rhythm came from people with higher blood markers of tau pathology and more shrinkage in memory related brain regions.
A Dutch cohort study of 269 cognitively unimpaired adults tested whether resting heart rate variability measured years earlier predicted later cognition, blood biomarkers or brain scans. It found almost no such link once coronary artery calcification was taken into account.
A methods paper in PAIN, posted online ahead of print on August 10, 2026, sets out for the first time how to run placebo trials in which nobody is fooled. It is written for pain research, but the design questions it raises reach into every trial that has a placebo arm, dementia trials included.
In a Taipei scanner, 31 healthy adults were given the same electric jolt over and over. What changed how much it hurt was not how reliable their expectation was, but how much feeling it carried. For anyone thinking about pain and dementia, that difference matters.
A multicenter European study put a finger prick against a needle in the arm, and asked whether a card of dried blood mailed at room temperature could carry the same signal. For people whose veins are hard to find, including adults with Down syndrome, the question is not academic.
At a cognitive neurology clinic, a voice AI ran the long history-taking interview while patients waited for their testing. A peer-reviewed SIGDIAL 2026 paper reports what it caught, and what it still cannot tell anyone.
A UC Davis preprint describes AI-Care, a voice-first agent for the small logistics of Alzheimer's life. Four women, mean age 84, tried it. What it records, and for whom, is the part clinicians should read closely.
A study of 344 cognitively healthy adults in the Baltimore Longitudinal Study of Aging paired seven days of wrist actigraphy with brain MRI, and found the link between a ragged 24-hour rhythm and shrinking brain tissue was clearest in the oldest participants. It is observational, the follow-up was short, and it diagnoses nobody.
A small molecule that already cleared human safety testing for spinal cord injury reduced neuronal DNA damage and brain inflammation in Alzheimer's mice, King's College London researchers report, though the study involved only a handful of animals and has not yet been tested in Alzheimer's patients.
A case-control study combining plasma chemistry with gut bacteria data in 85 people found a three-metabolite blood panel that distinguished Alzheimer's patients from cognitively normal controls, and flagged a cell-energy pathway the authors say deserves closer study, though they call the tool an aid, not a stand-alone diagnostic.
A PLOS Biology study of 72 adults, published on 2 March 2026, separated the strength of a pain expectation from its certainty, and found each one riding a different alpha rhythm in the anticipating brain. Basic mechanism work in healthy volunteers, not a treatment, and not a dementia study.
A narrative review published in Frontiers in Neurology in July argues that brief office tests and passive digital phenotyping are being treated as rivals when they do separate jobs, and that neither one hands a clinic a diagnosis.
A preprint from four University of Missouri researchers describes AgenticAD, a system of eight AI agents in which three of them interview a caregiver and produce an assessment summary, a daily plan and a follow-up schedule. It has been run on three invented personas and no real families.
A two-year-plus tracking study of 64 cognitively normal older adults found that overall sleep apnea severity did not predict changes in a blood ratio tied to brain amyloid, though one narrower signal in apnea-free participants did not survive statistical adjustment.
Months after a Dutch cohort found heart rate variability predicted almost nothing over 13 years, a peer-reviewed narrative review argues the metric was never meant to be read by itself. Its proposal: pair it with the brain's own electrical rhythm.
A new review in Aging and Disease argues melatonin's value to the brain lies in timing, not sedation. The metric missing from most of the evidence is the one the argument depends on.
A cluster-randomized trial in 38 primary care clinics is testing whether an alert built into the electronic health record can help clinicians catch cognitive impairment they might otherwise miss, with the first published results in on clinician confidence, not on diagnosis rates.
A scoping review in Alzheimer's & Dementia sifted 4,751 papers on the microbiota-gut-brain axis in mild cognitive impairment and Alzheimer's. What survived the sift says as much about the field's habits as about anyone's gut.
A pooled analysis of brain-scan data from 409 people finds that words alone and words paired with conditioning change pain-related brain activity in overlapping but partly different ways, a distinction researchers say matters for how future placebo-based protocols are designed and tested.
A February 2026 Nature review by Henrik Zetterberg and Barbara Bendlin gathers the scattered story of blood and spinal fluid tests across Alzheimer's and other neurodegenerative dementias, and shows plainly where the map runs out.
A UK feasibility study wore blinded Dexcom G7 sensors on 32 older inpatients with type 2 diabetes and cognitive impairment for up to 10 days, testing whether continuous glucose monitoring can be deployed on the ward at all, before any question of whether it changes outcomes.
A review in Alzheimer's & Dementia maps how falling NAD+ and the body's 24-hour timing machinery pull on each other in dementia. It is a map of mechanisms, not a treatment.
A plasma marker called eMTBR-tau243 tracks Alzheimer's tau tangles rather than amyloid. Three published cohorts say it works as a measure. None of them says yet who should be treated.
A study using smart ring data from 162 older adults found that variability in nightly sleep and heart rate patterns, tracked over months, distinguished mild cognitive impairment better than single average readings.
A baseline analysis of a randomized trial in 103 older adults with insomnia symptoms found no significant tie between actigraphy-measured sleep and plasma Alzheimer's biomarkers, but ambulatory EEG sleep-stage data, available in a subset of 56 participants, did show one.
Centre Hospitalier Universitaire de Nice is recruiting for AMPAlz, a study measuring peripheral mitochondrial function and metabolomic markers in blood, to see whether cellular energy metabolism outside the brain can serve as an early, accessible signal of Alzheimer's disease and related dementias.
A newly posted study on ClinicalTrials.gov describes a 10-person, pharmacist-led feasibility trial giving standard blood pressure and cholesterol drugs to APOE e4 carriers, part of a wider push to test whether managing vascular risk factors changes the course toward Alzheimer's disease.
A two-sample Mendelian randomization study reports that genetically predicted obstructive sleep apnea is tied to lower, not higher, odds of a general dementia diagnosis, a finding that runs against decades of observational research and that its own authors say needs replication.
Data presented at the Alzheimer's Association International Conference show family physicians using blood biomarker results reached accuracy nearly equal to dementia specialists, and far above their own accuracy without the test.
A global records analysis built to compare new melatonin users against new benzodiazepine and zolpidem users for dementia and Parkinson's disease outcomes found the reverse of the hoped-for result: melatonin starters had higher rates of diagnosis, not lower.
A new synthesis from Barcelona and London argues that brain aging is driven not only by misfolded protein, but by cells that have quit the cell cycle and will not stop signalling. It is a review, not a discovery, and the human evidence is still thin.
A study of 35 first-time, treatment-naive patients with late-onset Alzheimer's disease found widespread changes in blood lipids and amino acids that tracked with inflammatory markers, before any drug had entered the picture.
Three pre-registered experiments from the University of Toledo found that explaining the nocebo effect did not just shift how people felt about side effects. It changed how much side-effect information they went looking for, and it did not leave them more anxious.
By separating microglia, astrocytes and neurons from mouse brains and measuring their metabolites directly, researchers found microglia carry a distinct glutathione and polyamine chemistry that declines with normal aging and collapses further in an Alzheimer's mouse model, with disruption of the pathway followed by more amyloid buildup.
A preprint posted on medRxiv analyzes what drives large placebo improvements in trials of agitation in Alzheimer's disease and proposes trial-design changes meant to shrink that response, work aimed squarely at a problem that has undermined efforts to prove new drugs work.
An audit of records at one large academic health system found that a diagnosis of dementia or cognitive impairment barely moves the odds a caregiver has been granted shared access to a patient's electronic health record portal, a gap researchers say undercuts every other tool built on top of it.
A Pittsburgh and Carnegie Mellon team read gene activity and DNA folding in the same 23,825 brain cells from 20 postmortem donors, and found the architecture of the genome disturbed in Alzheimer's. The work is a map, not a mechanism, and every cell in it came from a brain after death.
A long-term follow-up of the DREAMS START trial found that sleep improvements in people with dementia were still detectable 24 months after the program began, though the family caregivers' own sleep did not improve.
In a controlled nine month experiment, mice given the short-chain fatty acids that gut bacteria make from fibre ended up with bigger hippocampi and better maze memory than mice given plain water. This is animal work, and it is early.
A new brain-imaging analysis of ADNI participants finds that a shrinking cluster of cholinergic neurons deep in the forebrain tracks with weaker infra-slow brain activity and with cortical tau spreading further as disease stage advances, an observational finding that stops short of proving cause.
A ballistocardiographic mat installed under participants' mattresses picked up advanced tau pathology as well as a blood test did in a presymptomatic cohort born in 1946, researchers reported at a scientific meeting. The finding comes from a conference abstract, not a validated diagnostic, and performed worse at earlier disease stages.
A month of round-the-clock wrist accelerometry in 68 older adults with early cognitive impairment found that earlier, not later, timing of peak daily activity tracked with higher amyloid-beta and tau on PET scans, and that fragmented daily rhythms tracked with tau in later-stage brain regions. The study is cross-sectional and cannot say which came first.
A handful of yes-or-no questions about sleep, answered by 1,325 Americans at an average age of 40, tracked with Alzheimer's blood markers measured two decades later. The study pushes the sleep question earlier than it has ever been asked, and shows how thin our measure of sleep still is.
A systematic review of 50 studies sorted electronic health record data into ten domains and found that cognitive and behavioural fields carried the diagnostic weight. It also found that most of the studies never reported how accurate they were.